guineensine has been researched along with anandamide* in 2 studies
2 other study(ies) available for guineensine and anandamide
Article | Year |
---|---|
Total Synthesis of the Endocannabinoid Uptake Inhibitor Guineensine and SAR Studies.
Guineensine ((2E,4E,12E)-13-(benzo[d][1,3]dioxol-5-yl)-N-isobutyltrideca-2,4,12-trienamide) is a plant-derived natural product that inhibits reuptake of the endocannabinoid anandamide with sub-micromolar potency. We have established a highly efficient total synthesis of guineensine, which provided the natural product in only five steps from commercially available 3-nonyn-1-ol in 17 % overall yield, relying on the attachment of the benzodioxolyl moiety to the unsaturated fatty acid chain by means of a Suzuki coupling as the key step. Subsequent SAR studies revealed that replacement of the N-isobutyl group in the natural product by various alkyl, arylalkyl, or aryl groups is generally well tolerated, and derivatives could be identified that are slightly more potent anandamide reuptake inhibitors than guineensine itself. In contrast, modifications of the benzodioxolyl moiety led to decreased activity. Intriguingly, a change in the configuration of the C4=C5 double bond from E to Z was found to be very well tolerated, in spite of the associated change in the overall geometry of the molecule. Topics: Alkenes; Arachidonic Acids; Biological Transport; Cell Line, Tumor; Endocannabinoids; Heterocyclic Compounds, 2-Ring; Humans; Molecular Structure; Polyunsaturated Alkamides; Structure-Activity Relationship | 2019 |
Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice.
High-content screening led to the identification of the N-isobutylamide guineensine from Piper nigrum as novel nanomolar inhibitor (EC50=290nM) of cellular uptake of the endocannabinoid anandamide (AEA). Noteworthy, guineensine did not inhibit endocannabinoid degrading enzymes fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL) nor interact with cannabinoid receptors or fatty acid binding protein 5 (FABP5), a major cytoplasmic AEA carrier. Activity-based protein profiling showed no inhibition of serine hydrolases. Guineensine also inhibited the cellular uptake of 2-arachidonoylglycerol (2-AG). Preliminary structure-activity relationships between natural guineensine analogs indicate the importance of the alkyl chain length interconnecting the pharmacophoric isobutylamide and benzodioxol moieties for AEA cellular uptake inhibition. Guineensine dose-dependently induced cannabimimetic effects in BALB/c mice shown by strong catalepsy, hypothermia, reduced locomotion and analgesia. The catalepsy and analgesia were blocked by the CB1 receptor antagonist rimonabant (SR141716A). Guineensine is a novel plant natural product which specifically inhibits endocannabinoid uptake in different cell lines independent of FAAH. Its scaffold may be useful to identify yet unknown targets involved in endocannabinoid transport. Topics: Alkenes; Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Biological Transport; Brain; Cannabinoid Receptor Antagonists; Catalepsy; Dose-Response Relationship, Drug; Endocannabinoids; Fatty Acid-Binding Proteins; Glycerides; Heterocyclic Compounds, 2-Ring; Humans; Hypothermia; Locomotion; Male; Mice; Mice, Inbred BALB C; Monoacylglycerol Lipases; Neoplasm Proteins; Piper; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Serine Endopeptidases; Structure-Activity Relationship; U937 Cells | 2014 |